Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

Stage III metastatic melanomas require adequate adjuvant immunotherapy to prevent relapses. Prognostic factors are awaited to optimize the clinical management of these patients. The magnitude of metastatic lymph node invasion and the BRAFV600 activating mutation have clinical significance. Based on...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Invest Dermatol
Main Authors: Jacquelot, Nicolas, Roberti, María Paula, Enot, David P., Rusakiewicz, Sylvie, Semeraro, Michaela, Jegou, Sarah, Flores, Camila, Chen, Lieping, Kwon, Byoung S., Borg, Christophe, Weide, Benjamin, Aubin, Frangois, Dalle, Stephane, Kohrt, Holbrook, Ayyoub, Maha, Kroemer, Guido, Marabelle, Aurelien, Cavalcanti, Andrea, Eggermont, Alexander, Zitvogel, Laurence
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156792/
https://ncbi.nlm.nih.gov/pubmed/26829031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jid.2015.12.042
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados